Share This

Related Topics News - Drugs

     
 < Previous page   Title only   |   Print    Next page > 
     
中生製藥發布FS222「CD137/PD-L1」一期陽性臨床數據

2024-06-05T  
中生製藥2025年到期零息可轉債換股價調整至每股11.86元

2024-06-05T  
石藥治療卵巢癌等口服抑制劑獲藥品註冊批件

2024-06-03T  
石四藥集團恩他卡朋片取得藥品生產註冊批件

2024-06-03T  
石四藥集團旗下高血壓藥通過國家藥監局一致性評價

2024-06-03T  
《大行》美銀證券上調石藥目標價至6.5元 首季表現輕微復甦

2024-06-03T  
《港股》恆指高開179點 電動車股急漲 蔚來升9%

2024-05-31T  
石四藥琥珀酸曲格列汀獲批准登記成為原料藥

2024-05-31T  
石四藥腹膜透析液通過仿製藥一致性評價

2024-05-30T  
《大行》交銀國際升石藥目標價至11元 首季成藥業務遠超預期

2024-05-29T  
 < Previous page    Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.